Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.

PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Male or female patients, 66 years or older, with a documented clinical diagnosis of Generalised Anxiety Disorder (GAD).

• Absence of current episode of major depression.

Exclusion Criteria:

• The presence of dementia or other mental disorder than GAD.

• Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse.

• A current diagnosis of cancer or current or past diagnosis of stroke.